| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Test Id : CRDPP
Creatine Disorders Panel, Plasma
Useful For
Suggests clinical disorders or settings where the test may be helpful
Suggests clinical disorders or settings where the test may be helpful
Evaluation of patients with a clinical suspicion of arginine:glycine amidinotransferase deficiency and guanidinoacetate methyltransferase deficiency.
This test is not useful for the diagnosis of creatine transporter deficiency.
Genetics Test Information
Provides information that may help with selection of the correct genetic test or proper submission of the test request
Provides information that may help with selection of the correct genetic test or proper submission of the test request
Depletion of cerebral creatine occurs in all 3 types of creatine deficiency syndromes (CDS): arginine:glycine amidinotransferase deficiency, guanidinoacetate methyltransferase deficiency, and creatine transporter deficiency.
Measurement of guanidinoacetate, creatine, and creatinine along with associated analyte ratios in plasma and urine distinguishes among the types of creatine deficiency syndromes.
Treatment with oral creatine supplementation is effective in some types of CDS.
Creatine supplementation may impact reliability of test results.
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
For more information, see Newborn Screening Act Sheet Guanidinoacetate Methyltransferase Deficiency: Increased Guanidinoacetate in Special Instructions.
The following algorithms are available in Special Instructions:
-Newborn Screen Follow-up for Guanidinoacetate Methyltransferase Deficiency (GAMT)
-Epilepsy: Unexplained Refractory and/or Familial Testing Algorithm
Special Instructions
Library of PDFs including pertinent information and forms related to the test
Library of PDFs including pertinent information and forms related to the test
Method Name
A short description of the method used to perform the test
A short description of the method used to perform the test
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Yes
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Lists a shorter or abbreviated version of the Published Name for a test
Creatine Disorders Panel, P
Aliases
Lists additional common names for a test, as an aid in searching
Lists additional common names for a test, as an aid in searching
AGAT (Arginine:Glycine Amidinotransferase) Deficiency
Arginine:Glycine Amidinotransferase Deficiency (AGAT)
Creatine disorders
Creatine plasma
Creatine/creatinine ratio plasma
Creatinine plasma
GAMT (Guanidinoacetate Methyltransferase) Deficiency
Guanidinoacetate
Guanidinoacetate Methyltransferase (GAMT) Deficiency
Guanidinoacetic acid (GAA)
L-Arginine:Glycine Amidinotransferase Deficiency (AGAT)
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
For more information, see Newborn Screening Act Sheet Guanidinoacetate Methyltransferase Deficiency: Increased Guanidinoacetate in Special Instructions.
The following algorithms are available in Special Instructions:
-Newborn Screen Follow-up for Guanidinoacetate Methyltransferase Deficiency (GAMT)
-Epilepsy: Unexplained Refractory and/or Familial Testing Algorithm
Specimen Type
Describes the specimen type validated for testing
Describes the specimen type validated for testing
Plasma
Ordering Guidance
For diagnosis of creatine transporter deficiency, order CRDPU / Creatine Disorders Panel, Random, Urine.
Additional Testing Requirements
To diagnose all creatine deficiency syndromes, order CRDPU / Creatine Disorders Panel, Random, Urine in addition to this test.
Necessary Information
Patient's age and sex are required.
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Collection Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Green top (sodium heparin), yellow top (ACD)
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot plasma into plastic vial. Send plasma frozen.
Special Instructions
Library of PDFs including pertinent information and forms related to the test
Library of PDFs including pertinent information and forms related to the test
Forms
1. Biochemical Genetics Patient Information (T602) in Special Instructions
2. If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory
0.1 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
Identifies specimen types and conditions that may cause the specimen to be rejected
| Gross hemolysis | OK |
| Gross lipemia | OK |
| Gross icterus | OK |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma | Frozen (preferred) | 14 days | |
| Refrigerated | 7 days | ||
| Ambient | 72 hours |
Useful For
Suggests clinical disorders or settings where the test may be helpful
Suggests clinical disorders or settings where the test may be helpful
Evaluation of patients with a clinical suspicion of arginine:glycine amidinotransferase deficiency and guanidinoacetate methyltransferase deficiency.
This test is not useful for the diagnosis of creatine transporter deficiency.
Genetics Test Information
Provides information that may help with selection of the correct genetic test or proper submission of the test request
Provides information that may help with selection of the correct genetic test or proper submission of the test request
Depletion of cerebral creatine occurs in all 3 types of creatine deficiency syndromes (CDS): arginine:glycine amidinotransferase deficiency, guanidinoacetate methyltransferase deficiency, and creatine transporter deficiency.
Measurement of guanidinoacetate, creatine, and creatinine along with associated analyte ratios in plasma and urine distinguishes among the types of creatine deficiency syndromes.
Treatment with oral creatine supplementation is effective in some types of CDS.
Creatine supplementation may impact reliability of test results.
Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
For more information, see Newborn Screening Act Sheet Guanidinoacetate Methyltransferase Deficiency: Increased Guanidinoacetate in Special Instructions.
The following algorithms are available in Special Instructions:
-Newborn Screen Follow-up for Guanidinoacetate Methyltransferase Deficiency (GAMT)
-Epilepsy: Unexplained Refractory and/or Familial Testing Algorithm
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Disorders of creatine synthesis (guanidinoacetate methyltransferase: GAMT, L-arginine:glycine amidinotransferases: AGAT, and creatine transporter deficiency: CTD) are collectively described as creatine deficiency syndromes (CDS). GAMT and AGAT deficiencies are inherited in an autosomal recessive manner, while CTD is X-linked. All 3 disorders result in a depletion of cerebral creatine and typically present with global developmental delays, intellectual disability, and severe speech delay. Affected patients may have abnormal magnetic resonance imaging findings and exhibit cerebral creatine deficiency in brain magnetic resonance spectroscopy. Patients with GAMT and male patients with CTD develop seizures, behavioral problems, and autistic features and may have abnormal movements. Female carriers for CTD can be asymptomatic or exhibit features similar to affected male patients such as intellectual disability, behavioral problems, and seizures.
Diagnosis of creatine synthesis disorders relies on measurement of guanidinoacetate (GAA), creatine (Cr), and creatinine (Crn) in serum and urine. The profiles are specific for each clinical entity. In serum, patients with GAMT deficiency typically exhibit very elevated GAA, low Cr, and normal to low Crn. Patients with AGAT deficiency typically exhibit low to normal GAA, low Cr, and normal to low Crn. In comparison, patients with CTD typically have normal serum levels of GAA, Cr and Crn, and measurement of these analytes in urine is required for diagnosis in male patients (characteristic findings are elevated Cr, normal to low Crn, and an elevated Cr:Crn ratio in urine). The only reliable method for diagnosis of CTD in female patients is molecular analysis of the SLC6A8 gene. The diagnosis of GAMT and AGAT can be confirmed by molecular analysis of GAMT and GATM.
Treatment with oral supplementation of creatine monohydrate is available and effective for the AGAT and GAMT deficiencies. Patients with GAMT deficiency may also be treated with supplemental ornithine and dietary arginine restriction.
Early treatment has been reported to prevent disease manifestations in affected but presymptomatic newborn siblings of individuals with GAMT or AGAT deficiencies.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
| Creatine Disorders Panel Reference Values | ||||||||||||
| | < or =11 Months | 12-23 Months | 24-35 Months | |||||||||
| Female | Male | Female | Male | Female | Male | |||||||
| Creatine | 38.6-96.8 | 39.0-97.0 | 38.2-96.5 | 38.6-96.5 | 37.7-96.0 | 38.2-96.0 | ||||||
| Creatinine | 27.6-35.9 | 27.6-35.2 | 27.6-36.5 | 27.6-35.5 | 27.6-37.1 | 27.6-36.0 | ||||||
| Guanidinoacetate | 0.7-2.0 | 0.7-2.1 | 0.7-2.0 | 0.7-2.1 | 0.7-2.0 | 0.7-2.1 | ||||||
| Creatine/ | < or =3.07 | < or =3.60 | < or =3.02 | < or =3.54 | < or =2.96 | < or =3.48 | ||||||
| Guanidinoacetate/ | < or =0.040 | < or =0.040 | < or =0.042 | < or =0.040 | < or =0.043 | < or =0.042 | ||||||
| Guanidinoacetate/ | < or =0.051 | < or =0.081 | < or =0.051 | < or =0.080 | < or =0.051 | < or =0.079 | ||||||
| | ||||||||||||
| | 3 Years | 4 Years | 5 Years | |||||||||
| Female | Male | Female | Male | Female | Male | |||||||
| Creatine | 37.1-95.5 | 37.7-95.3 | 36.0-94.4 | 36.8-94.1 | 34.6-93.2 | 35.6-92.7 | ||||||
| Creatinine | 27.6-37.9 | 27.7-36.9 | 27.6-39.3 | 27.7-38.2 | 27.6-40.9 | 27.8-39.9 | ||||||
| Guanidinoacetate | 0.7-2.1 | 0.7-2.2 | 0.7-2.1 | 0.7-2.2 | 0.7-2.1 | 0.7-2.2 | ||||||
| Creatine/ | < or =2.89 | < or =3.40 | < or =2.77 | < or =3.26 | < or =2.64 | < or =3.09 | ||||||
| Guanidinoacetate/ | < or =0.045 | < or =0.043 | < or =0.049 | < or =0.045 | < or =0.053 | < or =0.049 | ||||||
| Guanidinoacetate/ | < or =0.050 | < or =0.077 | < or =0.050 | < or =0.075 | < or =0.049 | < or =0.072 | ||||||
| | 6 Years | 7 Years | 8 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 33.0-91.7 | 34.3-91.0 | 31.2-90.0 | 32.7-89.2 | 29.2-88.1 | 31.0-87.3 |
| Creatinine | 27.6-42.8 | 28.0-41.9 | 27.7-44.9 | 28.3-44.3 | 27.8-47.0 | 28.8-47.1 |
| Guanidinoacetate | 0.7-2.1 | 0.7-2.3 | 0.7-2.1 | 0.8-2.3 | 0.8-2.1 | 0.8-2.4 |
| Creatine/ | < or =2.49 | < or =2.91 | < or =2.33 | < or =2.70 | < or =2.17 | < or =2.49 |
| Guanidinoacetate/ | < or =0.058 | < or =0.053 | < or =0.063 | < or =0.058 | < or =0.069 | < or =0.064 |
| Guanidinoacetate/ | < or =0.049 | < or =0.069 | < or =0.048 | < or =0.066 | < or =0.047 | < or =0.063 |
| | 9 Years | 10 Years | 11 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 27.2-85.9 | 29.3-85.2 | 25.2-83.7 | 27.4-83.1 | 23.4-81.3 | 25.7-80.9 |
| Creatinine | 28.0-49.3 | 29.5-50.1 | 28.2-51.5 | 30.6-53.6 | 28.4-53.6 | 32.0-57.2 |
| Guanidinoacetate | 0.8-2.2 | 0.8-2.5 | 0.9-2.2 | 0.9-2.6 | 0.9-2.2 | 1.0-2.6 |
| Creatine/ | < or =2.02 | < or =2.28 | < or =1.86 | < or =2.07 | < or =1.72 | < or =1.87 |
| Guanidinoacetate/ | < or =0.075 | < or =0.070 | < or =0.081 | < or =0.078 | < or =0.087 | < or =0.085 |
| Guanidinoacetate/ | < or =0.047 | < or =0.060 | < or =0.046 | < or =0.057 | < or =0.045 | < or =0.055 |
| | 12 Years | 13 Years | 14 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 21.7-78.7 | 23.9-78.6 | 20.3-76.2 | 22.3-76.2 | 19.0-73.6 | 20.8-73.8 |
| Creatinine | 28.7-55.7 | 33.8-61.0 | 29.1-57.7 | 35.9-64.8 | 29.5-59.5 | 38.1-68.5 |
| Guanidinoacetate | 0.9-2.2 | 1.0-2.7 | 1.0-2.3 | 1.1-2.8 | 1.0-2.3 | 1.1-2.9 |
| Creatine/ | < or =1.58 | < or =1.68 | < or =1.45 | < or =1.50 | < or =1.33 | < or =1.34 |
| Guanidinoacetate/ | < or =0.092 | < or =0.093 | < or =0.097 | < or =0.101 | < or =0.101 | < or =0.109 |
| Guanidinoacetate/ | < or =0.044 | < or =0.053 | < or =0.043 | < or =0.051 | < or =0.042 | < or =0.050 |
| | 15 Years | 16 Years | 17 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 18.1-71.1 | 19.5-71.2 | 17.4-68.7 | 18.4-68.6 | 16.9-66.5 | 17.4-65.9 |
| Creatinine | 29.9-61.3 | 40.4-71.9 | 30.4-62.9 | 42.4-75.0 | 30.9-64.4 | 44.2-77.6 |
| Guanidinoacetate | 1.0-2.3 | 1.2-2.9 | 1.1-2.3 | 1.3-3.0 | 1.1-2.3 | 1.3-3.1 |
| Creatine/ | < or =1.22 | < or =1.20 | < or =1.12 | < or =1.07 | < or =1.04 | < or =0.97 |
| Guanidinoacetate/ | < or =0.104 | < or =0.117 | < or =0.107 | < or =0.125 | < or =0.109 | < or =0.132 |
| Guanidinoacetate/ | < or =0.041 | < or =0.049 | < or =0.040 | < or =0.048 | < or =0.040 | < or =0.048 |
| | 18 Years | 19 Years | 20 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 16.7-64.4 | 16.6-63.3 | 16.6-62.7 | 15.8-60.7 | 16.5-61.1 | 15.2-58.3 |
| Creatinine | 31.3-65.8 | 45.6-80.0 | 31.8-67.0 | 46.7-82.0 | 32.2-68.2 | 47.4-83.9 |
| Guanidinoacetate | 1.1-2.4 | 1.4-3.1 | 1.1-2.4 | 1.4-3.2 | 1.1-2.4 | 1.5-3.2 |
| Creatine/ | < or =0.98 | < or =0.87 | < or =0.93 | < or =0.80 | < or =0.89 | < or =0.73 |
| Guanidinoacetate/ | < or =0.111 | < or =0.139 | < or =0.112 | < or =0.145 | < or =0.113 | < or =0.150 |
| Guanidinoacetate/ | < or =0.039 | < or =0.047 | < or =0.038 | < or =0.047 | < or =0.038 | < or =0.046 |
| | 21 Years | 22 Years | 23 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 16.6-59.8 | 14.7-56.0 | 16.6-58.8 | 14.2-54.0 | 16.7-57.9 | 13.7-52.2 |
| Creatinine | 32.5-69.2 | 47.9-85.6 | 32.8-70.2 | 48.2-87.2 | 33.1-71.1 | 48.4-88.8 |
| Guanidinoacetate | 1.1-2.4 | 1.5-3.2 | 1.1-2.5 | 1.5-3.3 | 1.1-2.5 | 1.6-3.3 |
| Creatine/ | < or =0.87 | < or =0.68 | < or =0.85 | < or =0.64 | < or =0.84 | < or =0.61 |
| Guanidinoacetate/ | < or =0.114 | < or =0.156 | < or =0.115 | < or =0.161 | < or =0.116 | < or =0.165 |
| Guanidinoacetate/ | < or =0.037 | < or =0.045 | < or =0.037 | < or =0.045 | < or =0.037 | < or =0.044 |
| | 24 Years | 25 Years | 26 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 16.7-57.2 | 13.3-50.6 | 16.7-56.5 | 12.9-49.3 | 16.7-56.0 | 12.5-48.1 |
| Creatinine | 33.3-71.9 | 48.6-90.2 | 33.6-72.8 | 48.7-91.5 | 33.7-73.6 | 48.9-92.7 |
| Guanidinoacetate | 1.1-2.5 | 1.6-3.3 | 1.1-2.5 | 1.6-3.3 | 1.1-2.6 | 1.6-3.4 |
| Creatine/ | < or =0.84 | < or =0.58 | < or =0.84 | < or =0.56 | < or =0.84 | < or =0.54 |
| Guanidinoacetate/ | < or =0.116 | < or =0.170 | < or =0.117 | < or =0.174 | < or =0.118 | < or =0.179 |
| Guanidinoacetate/ | < or =0.036 | < or =0.043 | < or =0.036 | < or =0.043 | < or =0.036 | < or =0.042 |
| | 27 Years | 28 Years | 29 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 16.7-55.5 | 12.1-47.1 | 16.6-55.1 | 11.8-46.3 | 16.5-54.7 | 11.5-45.4 |
| Creatinine | 33.9-74.4 | 49.0-93.7 | 34.1-75.2 | 49.1-94.5 | 34.2-76.0 | 49.2-95.3 |
| Guanidinoacetate | 1.1-2.6 | 1.6-3.4 | 1.1-2.6 | 1.6-3.4 | 1.1-2.6 | 1.6-3.4 |
| Creatine/ | < or =0.84 | < or =0.52 | < or =0.84 | < or =0.51 | < or =0.84 | < or =0.49 |
| Guanidinoacetate/ | < or =0.118 | < or =0.182 | < or =0.119 | < or =0.186 | < or =0.119 | < or =0.188 |
| Guanidinoacetate/ | < or =0.036 | < or =0.042 | < or =0.036 | < or =0.041 | < or =0.036 | < or =0.041 |
| | 30 Years | 31 Years | 32 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 16.4-54.2 | 11.3-44.7 | 16.4-53.8 | 11.1-43.9 | 16.3-53.4 | 11.0-43.2 |
| Creatinine | 34.4-76.8 | 49.3-96.0 | 34.6-77.5 | 49.3-96.7 | 34.7-78.2 | 49.4-97.4 |
| Guanidinoacetate | 1.2-2.7 | 1.6-3.5 | 1.2-2.7 | 1.6-3.5 | 1.2-2.7 | 1.6-3.5 |
| Creatine/ | < or =0.84 | < or =0.48 | < or =0.83 | < or =0.47 | < or =0.83 | < or =0.46 |
| Guanidinoacetate/ | < or =0.120 | < or =0.190 | < or =0.120 | < or =0.192 | < or =0.119 | < or =0.192 |
| Guanidinoacetate/ | < or =0.036 | < or =0.041 | < or =0.036 | < or =0.042 | < or =0.037 | < or =0.042 |
| | 33 Years | 34 Years | 35 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 16.3-53.0 | 10.9-42.5 | 16.4-52.7 | 10.8-41.7 | 16.4-52.3 | 10.7-41.0 |
| Creatinine | 34.9-78.8 | 49.4-98.0 | 35.1-79.4 | 49.5-98.6 | 35.3-79.9 | 49.5-99.2 |
| Guanidinoacetate | 1.2-2.8 | 1.6-3.5 | 1.2-2.8 | 1.6-3.5 | 1.2-2.8 | 1.6-3.4 |
| Creatine/ | < or =0.82 | < or =0.45 | < or =0.82 | < or =0.45 | < or =0.82 | < or =0.44 |
| Guanidinoacetate/ | < or =0.119 | < or =0.192 | < or =0.118 | < or =0.191 | < or =0.118 | < or =0.189 |
| Guanidinoacetate/ | < or =0.037 | < or =0.042 | < or =0.037 | < or =0.042 | < or =0.037 | < or =0.042 |
| | 36 Years | 37 Years | 38 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 16.5-52.0 | 10.7-40.2 | 16.7-51.6 | 10.6-39.5 | 16.9-51.3 | 10.6-38.9 |
| Creatinine | 35.4-80.3 | 49.5-99.8 | 35.6-80.7 | 49.5-100.3 | 35.8-81.0 | 49.6-100.8 |
| Guanidinoacetate | 1.2-2.8 | 1.6-3.4 | 1.2-2.8 | 1.6-3.4 | 1.2-2.9 | 1.6-3.4 |
| Creatine/ | < or =0.82 | < or =0.44 | < or =0.82 | < or =0.44 | < or =0.83 | < or =0.44 |
| Guanidinoacetate/ | < or =0.117 | < or =0.187 | < or =0.115 | < or =0.184 | < or =0.114 | < or =0.182 |
| Guanidinoacetate/ | < or =0.037 | < or =0.042 | < or =0.037 | < or =0.042 | < or =0.036 | < or =0.042 |
| | 39 Years | 40 Years | 41 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 17.1-51.1 | 10.6-38.2 | 17.3-50.9 | 10.7-37.7 | 17.5-50.8 | 10.7-37.2 |
| Creatinine | 35.9-81.4 | 49.6-101.3 | 36.0-81.6 | 49.6-101.7 | 36.1-81.9 | 49.7-102.1 |
| Guanidinoacetate | 1.2-2.9 | 1.6-3.4 | 1.2-2.9 | 1.6-3.4 | 1.2-2.9 | 1.6-3.4 |
| Creatine/ | < or =0.83 | < or =0.44 | < or =0.83 | < or =0.44 | < or =0.84 | < or =0.44 |
| Guanidinoacetate/ | < or =0.113 | < or =0.179 | < or =0.111 | < or =0.176 | < or =0.110 | < or =0.174 |
| Guanidinoacetate/ | < or =0.036 | < or =0.041 | < or =0.036 | < or =0.041 | < or =0.036 | < or =0.040 |
| | 42 Years | 43 Years | 44 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 17.7-50.8 | 10.8-36.7 | 17.8-50.8 | 10.9-36.3 | 17.8-50.9 | 11.0-36.0 |
| Creatinine | 36.2-82.1 | 49.7-102.5 | 36.3-82.4 | 49.8-102.8 | 36.4-82.6 | 49.8-103.1 |
| Guanidinoacetate | 1.2-3.0 | 1.6-3.3 | 1.2-3.0 | 1.6-3.3 | 1.2-3.0 | 1.6-3.3 |
| Creatine/ | < or =0.84 | < or =0.44 | < or =0.84 | < or =0.43 | < or =0.84 | < or =0.43 |
| Guanidinoacetate/ | < or =0.109 | < or =0.172 | < or =0.108 | < or =0.171 | < or =0.107 | < or =0.170 |
| Guanidinoacetate/ | < or =0.036 | < or =0.039 | < or =0.036 | < or =0.039 | < or =0.036 | < or =0.038 |
| | 45 Years | 46 Years | 47 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 17.7-51.0 | 11.1-35.6 | 17.6-51.2 | 11.2-35.3 | 17.4-51.4 | 11.3-35.1 |
| Creatinine | 36.4-82.8 | 49.9-103.4 | 36.5-83.0 | 49.9-103.6 | 36.5-83.2 | 49.9-103.9 |
| Guanidinoacetate | 1.2-3.0 | 1.7-3.3 | 1.2-3.1 | 1.7-3.3 | 1.2-3.1 | 1.7-3.3 |
| Creatine/ | < or =0.84 | < or =0.42 | < or =0.83 | < or =0.41 | < or =0.83 | < or =0.40 |
| Guanidinoacetate/ | < or =0.106 | < or =0.169 | < or =0.106 | < or =0.168 | < or =0.106 | < or =0.167 |
| Guanidinoacetate/ | < or =0.037 | < or =0.038 | < or =0.037 | < or =0.037 | < or =0.037 | < or =0.037 |
| | 48 Years | 49 Years | 50 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 17.2-51.7 | 11.5-34.8 | 17.1-51.9 | 11.6-34.6 | 17.0-52.1 | 11.7-34.4 |
| Creatinine | 36.6-83.4 | 49.9-104.1 | 36.6-83.5 | 49.9-104.2 | 36.7-83.7 | 49.9-104.4 |
| Guanidinoacetate | 1.2-3.1 | 1.7-3.3 | 1.2-3.1 | 1.7-3.3 | 1.2-3.1 | 1.7-3.3 |
| Creatine/ | < or =0.82 | < or =0.39 | < or =0.82 | < or =0.38 | < or =0.82 | < or =0.38 |
| Guanidinoacetate/ | < or =0.106 | < or =0.166 | < or =0.106 | < or =0.164 | < or =0.105 | < or =0.163 |
| Guanidinoacetate/ | < or =0.038 | < or =0.036 | < or =0.038 | < or =0.036 | < or =0.039 | < or =0.036 |
| | 51 Years | 52 Years | 53 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 17.0-52.2 | 11.9-34.3 | 17.1-52.3 | 12.0-34.3 | 17.3-52.4 | 12.2-34.3 |
| Creatinine | 36.8-83.9 | 49.8-104.6 | 36.8-84.0 | 49.8-104.8 | 36.9-84.2 | 49.8-104.9 |
| Guanidinoacetate | 1.2-3.1 | 1.7-3.3 | 1.2-3.1 | 1.7-3.2 | 1.2-3.1 | 1.6-3.2 |
| Creatine/ | < or =0.82 | < or =0.37 | < or =0.82 | < or =0.37 | < or =0.82 | < or =0.38 |
| Guanidinoacetate/ | < or =0.105 | < or =0.161 | < or =0.104 | < or =0.159 | < or =0.103 | < or =0.157 |
| Guanidinoacetate/ | < or =0.039 | < or =0.036 | < or =0.039 | < or =0.036 | < or =0.039 | < or =0.036 |
| | 54 Years | 55 Years | 56 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 17.6-52.5 | 12.4-34.3 | 18.1-52.6 | 12.5-34.4 | 18.6-52.7 | 12.6-34.4 |
| Creatinine | 37.0-84.4 | 49.8-105.0 | 37.1-84.5 | 49.8-105.2 | 37.2-84.7 | 49.8-105.3 |
| Guanidinoacetate | 1.2-3.1 | 1.6-3.2 | 1.2-3.1 | 1.6-3.2 | 1.2-3.1 | 1.6-3.2 |
| Creatine/ | < or =0.82 | < or =0.38 | < or =0.83 | < or =0.39 | < or =0.84 | < or =0.40 |
| Guanidinoacetate/ | < or =0.102 | < or =0.155 | < or =0.100 | < or =0.154 | < or =0.099 | < or =0.152 |
| Guanidinoacetate/ | < or =0.039 | < or =0.036 | < or =0.039 | < or =0.036 | < or =0.039 | < or =0.036 |
| | 57 Years | 58 Years | 59 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 19.2-52.9 | 12.7-34.4 | 19.9-53.1 | 12.8-34.3 | 20.5-53.3 | 12.8-34.2 |
| Creatinine | 37.3-84.9 | 49.8-105.4 | 37.4-85.1 | 49.8-105.5 | 37.6-85.2 | 49.8-105.6 |
| Guanidinoacetate | 1.2-3.0 | 1.6-3.2 | 1.3-3.0 | 1.6-3.2 | 1.3-3.0 | 1.6-3.2 |
| Creatine/ | < or =0.84 | < or =0.40 | < or =0.85 | < or =0.41 | < or =0.86 | < or =0.42 |
| Guanidinoacetate/ | < or =0.098 | < or =0.151 | < or =0.096 | < or =0.151 | < or =0.095 | < or =0.150 |
| Guanidinoacetate/ | < or =0.039 | < or =0.036 | < or =0.038 | < or =0.036 | < or =0.038 | < or =0.036 |
| | 60 Years | 61 Years | 62 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 21.0-53.6 | 12.8-34.1 | 21.5-53.9 | 12.7-34.0 | 21.9-54.2 | 12.6-33.9 |
| Creatinine | 37.8-85.4 | 49.9-105.7 | 38.0-85.5 | 49.9-105.9 | 38.3-85.7 | 49.9-106.0 |
| Guanidinoacetate | 1.3-2.9 | 1.6-3.2 | 1.3-2.9 | 1.6-3.1 | 1.3-2.9 | 1.6-3.1 |
| Creatine/ | < or =0.87 | < or =0.43 | < or =0.87 | < or =0.44 | < or =0.88 | < or =0.44 |
| Guanidinoacetate/ | < or =0.094 | < or =0.150 | < or =0.093 | < or =0.150 | < or =0.093 | < or =0.150 |
| Guanidinoacetate/ | < or =0.037 | < or =0.036 | < or =0.036 | < or =0.035 | < or =0.036 | < or =0.035 |
| | 63 Years | 64 Years | 65 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 22.2-54.6 | 12.4-33.7 | 22.3-55.0 | 12.3-33.6 | 22.5-55.5 | 12.2-33.4 |
| Creatinine | 38.7-85.8 | 50.0-106.1 | 39.1-85.9 | 50.0-106.3 | 39.6-86.1 | 50.1-106.4 |
| Guanidinoacetate | 1.3-2.8 | 1.6-3.1 | 1.3-2.8 | 1.6-3.1 | 1.3-2.8 | 1.6-3.1 |
| Creatine/ | < or =0.88 | < or =0.45 | < or =0.89 | < or =0.46 | < or =0.89 | < or =0.46 |
| Guanidinoacetate/ | < or =0.092 | < or =0.150 | < or =0.092 | < or =0.149 | < or =0.091 | < or =0.149 |
| Guanidinoacetate/ | < or =0.035 | < or =0.035 | < or =0.034 | < or =0.034 | < or =0.034 | < or =0.034 |
| | 66 Years | 67 Years | 68 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 22.6-55.9 | 12.3-33.1 | 22.7-56.3 | 12.3-32.8 | 22.9-56.7 | 12.5-32.4 |
| Creatinine | 40.2-86.2 | 50.2-106.6 | 40.7-86.3 | 50.3-106.7 | 41.3-86.5 | 50.4-106.9 |
| Guanidinoacetate | 1.3-2.7 | 1.6-3.1 | 1.3-2.7 | 1.6-3.0 | 1.4-2.7 | 1.6-3.0 |
| Creatine/ | < or =0.90 | < or =0.47 | < or =0.90 | < or =0.48 | < or =0.90 | < or =0.48 |
| Guanidinoacetate/ | < or =0.091 | < or =0.149 | < or =0.090 | < or =0.148 | < or =0.090 | < or =0.148 |
| Guanidinoacetate/ | < or =0.034 | < or =0.034 | < or =0.033 | < or =0.034 | < or =0.033 | < or =0.034 |
| | 69 Years | 70 Years | > or = 71 Years | |||
| Female | Male | Female | Male | Female | Male | |
| Creatine | 23.2-57.0 | 12.8-32.0 | 23.6-57.2 | 13.1-31.4 | 24.1-57.3 | 13.6-30.8 |
| Creatinine | 41.9-86.6 | 50.5-107.1 | 42.4-86.8 | 50.7-107.4 | 42.8-86.9 | 50.8-107.6 |
| Guanidinoacetate | 1.4-2.6 | 1.6-3.0 | 1.4-2.6 | 1.6-3.0 | 1.4-2.5 | 1.5-3.0 |
| Creatine/ | < or =0.90 | < or =0.48 | < or =0.90 | < or =0.48 | < or =0.90 | < or =0.48 |
| Guanidinoacetate/ | < or =0.090 | < or =0.148 | < or =0.090 | < or =0.148 | < or =0.090 | < or =0.148 |
| Guanidinoacetate/ | < or =0.033 | < or =0.034 | < or =0.033 | < or =0.034 | < or =0.033 | < or =0.034 |
Interpretation
Provides information to assist in interpretation of the test results
Provides information to assist in interpretation of the test results
Reports include concentrations of guanidinoacetate, creatine, and creatinine, and the calculated analyte ratios. When no significant abnormalities are detected, a simple descriptive interpretation is provided. When abnormal results are detected, a detailed interpretation is given. This interpretation includes an overview of the results and their significance, a correlation to available clinical information, elements of differential diagnosis, and recommendations for additional biochemical testing.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Creatine supplementation will cause falsely elevated creatine results and falsely decreased guanidinoacetate results.
Guanidinoacetate can be elevated in patients with urea cycle defects.
Clinical Reference
Recommendations for in-depth reading of a clinical nature
Recommendations for in-depth reading of a clinical nature
1. Clark JF, Cecil KM: Diagnostic methods and recommendations for the cerebral creatine deficiency syndromes. Pediatr Res; 2015 Mar;77(3):398-405
2. Mercimek-Mahmutoglu S, Salomons GS: Creatine deficiency syndromes. In: Pagon RA, Adam MP, Ardinger HH, et al. eds. GeneReviews [Internet]. University of Washington, Seattle; Jan 15 2009. Updated 2015 Dec 10. Accessed 2019 Dec 4. Available at www.ncbi.nlm.nih.gov/books/NBK3794/
3. Stockler S, Schultz PW, Salomons GS: Cerebral creatine deficiency syndromes: clinical aspects, treatment, and pathophysiology. Subcell Biochem. 2007;46:149-166
4. Longo N, Ardon O, Vanzo R, et al: Disorders of creatine transport and metabolism. Am J Med Genet. 2011;157:72-78 doi: 10.1002/ajmg.c.30292
Special Instructions
Library of PDFs including pertinent information and forms related to the test
Library of PDFs including pertinent information and forms related to the test
Method Description
Describes how the test is performed and provides a method-specific reference
Describes how the test is performed and provides a method-specific reference
A plasma sample is combined with stable isotope-labeled internal standards and acetonitrile. After centrifugation, an aliquot of this diluted sample is analyzed by injection onto liquid chromatography columns that separate the analytes from the bulk of the stable isotope dilution in the positive electrospray selected reaction monitoring mode using the Applied Biosystems API 3200 liquid chromatography-tandem mass spectrometry (LC-MS/MS) System with Analyst Software.(Bodamer OA, Bloesch SM, Gregg AR, et al: Analysis of guanidinoacetate and creatine by isotope dilution electroscopy tandem mass spectrometry. Clin Chim Acta. 2001;308:173-178; Cognat S, Cheillan D, Piraud M, et al: Determination of guanidinoacetate and creatine in urine and plasma by liquid chromatography-tandem mass spectrometry. Clin Chem. 2004;50:1459-1461; Sharer JD, Bodamer O, Longo N, Tortorelli S, Wamelink M, Young S: Laboratory diagnosis of creatine deficiency syndromes: a technical standard and guideline of the American College of Medical Genetics and Genomics. Genet Med. 2017 Feb;19[2]:256-263)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Indicates whether the report includes an additional document with charts, images or other enriched information
No
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Tuesday; 12 p.m.
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
2 to 9 days
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
1 month
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Indicates the location of the laboratory that performs the test
Rochester
Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
82540
82565
82542
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| CRDPP | Creatine Disorders Panel, P | In Process |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| 608071 | Interpretation | 59462-2 |
| 608072 | Creatine | 15045-8 |
| 608073 | Creatinine | 14682-9 |
| 608074 | Guanidinoacetate | 33244-5 |
| 608075 | Creatine/Creatinine | In Process |
| 610624 | Guanidinoacetate/Creatine | In Process |
| 610856 | Guanidinoacetate/Creatinine | In Process |
| 608076 | Reviewed By | 18771-6 |
Test Setup Resources
Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.
Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.
Normal and Abnormal sample reports are provided as references for report appearance.
SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.
Test Update Resources
| Change Type | Effective Date |
|---|---|
| New Test | 2021-08-24 |